Kolltan Pharmaceuticals Obtains $10,000,000 Series B Round

  • Feed Type
  • Date
    1/20/2010
  • Company Name
    Kolltan Pharmaceuticals
  • Mailing Address
    300 George St New Haven, CT 06511
  • Company Description
    Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need.
  • Website
    http://www.kolltan.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $10,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from these investments will be used to advance Kolltan’s therapeutic development pipeline.
  • M&A Terms
  • Venture Investor
    Celtic Therapeutics
  • Venture Investor
    Tichenor Ventures

By posting a comment, you agree to our terms and conditions.